In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK partners with Pentraxin on amyloidosis treatment

Executive Summary

GlaxoSmithKline and private UK biotech Pentraxin Therapeutics (spun off from University College London) have agreed to collaborate on the latter's preclinical small molecule/antibody combination for amyloidosis, a protein misfolding disorder in which amyloid accumulates in organs and tissues such as the heart, kidneys, liver, spleen, nervous system, and GI tract.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies